Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: FT
Drug: S-1

First Posted Date: 2006-11-16

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 12

Registration Number: NCT00400023

Locations: 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Clinical Trial of Chemosensitivity Test

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1

First Posted Date: 2006-02-07

Last Posted Date: 2011-06-29

Lead Sponsor: Japan Clinical Cancer Research Organization

Target Recruit Count: 300

Registration Number: NCT00287755

Locations: 🇯🇵
Kanazawa Medical University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵
St. Marianna University, School of Medicine, Kawasaki, Kanagawa, Japan
🇯🇵
Osaka Medical College Hospital, Takatsuki, Osaka, Japan

and more 33 locations

Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: docetaxel + S-1
Drug: S-1

First Posted Date: 2006-02-07

Last Posted Date: 2011-06-28

Lead Sponsor: Japan Clinical Cancer Research Organization

Target Recruit Count: 628

Registration Number: NCT00287768

Locations: 🇯🇵
Kanazawa Medical University Hospital, Kawakita, Ishikawa, Japan
🇯🇵
Iwate Medical University Hospital, Morioka, Iwate, Japan
🇯🇵
Kitasato University East Hospital, Sagamihara, Kanagawa, Japan

and more 113 locations

Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: S-1

First Posted Date: 2006-01-19

Last Posted Date: 2014-02-25

Lead Sponsor: Asan Medical Center

Target Recruit Count: 96

Registration Number: NCT00278863

Locations: 🇰🇷
Seoul Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷
Kyung Pook National University Hospital, Daegu, Korea, Republic of

and more 6 locations

Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2006-04-21

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 24

Registration Number: NCT00209638

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 2

Suspended

Conditions: Gastric Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2006-02-02

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 40

Registration Number: NCT00209664

Locations: 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1

Suspended

Conditions: Pancreatic Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2007-11-01

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 40

Registration Number: NCT00209677

Locations: 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

Phase 2

Conditions: Gastric Cancer
Esophageal Cancer
Pancreatic Cancer
Colon Cancer

First Posted Date: 2005-09-20

Last Posted Date: 2006-03-22

Lead Sponsor: Hamamatsu University

Registration Number: NCT00197431

Locations: 🇯🇵
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: S-1 plus CDDP
Drug: 5-FU plus CDDP

First Posted Date: 2005-09-20

Last Posted Date: 2011-07-07

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT00202969

Locations: 🇨🇳
Beijing Cancer Hospital, No.52 Fu-Cheng Road, Hai-dian District, Beijing, China

Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

First Posted Date: 2003-11-13

Last Posted Date: 2024-06-26

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 41

Registration Number: NCT00072787

Locations: 🇺🇸
Lovelace Sandia Health System, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico - Albuquerque, Albuquerque, New Mexico, United States
🇺🇸
New Mexico VA Health Care System, Albuquerque, New Mexico, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy